Receptor-Mediated Uptake of an Extracellular Bcl-XL Fusion Protein Inhibits Apoptosis


The present invention relates to the field of apoptosis, in particular, it relates to apoptosis-modifying fusion proteins with at least two domains, one of which targets the fusion proteins to a target cell, and another of which modifies an apoptotic response of the target cell. For example, fusing various cell-binding domains to Bcl-XL and Bad allows targeting to specific subsets of cells in vivo, permitting treatment and/or prevention of cell-death related consequences of various diseases and injuries. This technology could be used to minimize or prevent apoptotic damage that can be caused by neurodegenerative disorders, e.g., Alzheimer's disease, Huntington's disease or spinal-muscular atrophy, stroke episodes or transient ischemic neuronal injury, e.g., spinal cord injuries. Additionally, apoptotic-enhancing fusion proteins of the current invention could be used to inhibit cell growth, e.g., uncontrolled cellular proliferation.

Inventors:

Richard Youle (NINDS)  ➽ more inventions...


Intellectual Property:
U.S. Pat: 6,737,511 issued 2004-05-18
US Application No. 09/639,245
US Application No. 12/147,924
US Application No. 60/149,220
US Application No. PCT/US00/22293

Licensing Contact:
Olufunmilola (Lola) Olufemi,
Email: olufunmilola.olufemi@nih.gov
Phone: 301-451-3748

OTT Reference No: E-073-1999/0
Updated: Sep 1, 2000